To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Clopidogrel Not Contraindicated Before Kidney Transplantation, Study Results Suggest: Presented at ATC
URL: http://www.pslgroup.com/dg/2231F6.htm
Doctor's Guide
June 6, 2008

By Thomas S. May

TORONTO -- June 6, 2008 -- Patients should not be required to stop taking the antiplatelet agent clopidogrel before kidney transplantation, according to the results of a study presented here at the 2008 American Transplant Congress (ATC).

An increasing number of patients with kidney failure are now on clopidogrel and, currently, several transplant centres do not put these patients on the kidney transplant waiting list until they are off the drug. Therefore, patients have to decide whether they continue taking clopidogrel and remain on dialysis or stop taking it while waiting for a kidney transplant and increase their risk of thrombosis.

To determine the safety of continuing to take clopidogrel in kidney transplant recipients, William Bry, MD, California Pacific Medical Center, San Francisco, California, and colleagues conducted a retrospective study that compared patients undergoing transplantation while on clopidogrel and patients transplanted without anticoagulation.

The study findings were presented in a poster session on June 2.

Living-donor recipients who had been taking clopidogrel prior to the transplantation procedure and patients on warfarin were excluded from the analysis. Patients receiving acetylsalicylic acid (ASA) were included.

The researchers enrolled 25 patients who received clopidogrel up to the time of transplantation and 50 control subjects not on clopidogrel who underwent transplantation immediately before or after a clopidogrel-treated recipient.

The investigators found that 40% of patients in the clopidogrel group and 14% of patients in the control group needed blood transfusions (P = .01). Seven (58.3%) of 12 patients who were on both ASA and clopidogrel required blood transfusions, while 3 (23%) of 13 patients on clopidogrel alone needed blood transfusions (P = .07).

Patient and graft survival at 3-months post-transplantation was 100% in both groups.

According to the investigators, these results indicate that clopidogrel use should not be a contraindication to kidney transplantation. They noted, however, that, although kidney transplantation appears to be safe in patients receiving clopidogrel, they are at an increased risk of requiring transfusion of blood and/or blood products. Moreover, patients on both clopidogrel and ASA appear to be at an even greater risk of requiring transfusion.


[Presentation title: Kidney Transplantation on Plavix: Feasible or Foolhardy? Abstract 1272]

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.